Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clairleaf TM long-term BI 1291583 extension study in bronchiectasis
NL-OMON59627Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of verducatib in bronchiectasis, sponsored by Boehringer Ingelheim. Started Oct 2023; status: active, not recruiting.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NL-OMON59627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59627.